Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations


Por: Bernardo-Castineira C, Valdes N, Celada L, Martinez A, Saenz-de-Santa-Maria I, Bayon G, Fernandez A, Sierra M, Fraga M, Astudillo A, Jimenez-Fonseca P, Ria J, Hevia M, Turienzo E, Bernardo C, Forga L, Tena I, Molina-Garrido M, Cacho L, Villabona C, Serrano T, Scola B, Chirivella I, del Olmo M, Menendez C, Navarro E, Tous M, Vallejo A, Athimulam S, Bancos I, Suarez C, Chiara M

Publicada: 1 nov 2019
Resumen:
Context: SDHB mutations are found in an increasing number of neoplasms, most notably in paragangliomas and pheochromocytomas (PPGLs). SDHB-PPGLs are slow-growing tumors, but similar to 50% of them may develop metastasis. The molecular basis of metastasis in these tumors is a long-standing and unresolved problem. Thus, a better understanding of the biology of metastasis is needed. Objective: This study aimed to identify gene methylation changes relevant for metastatic SDHB-PPGLs. Design: We performed genome-wide profiling of DNA methylation in diverse clinical and genetic PPGL subtypes, and validated protocadherin gamma-C3 (PCDHGC3) gene promoter methylation in metastatic SDHB-PPGLs. Results: We define an epigenetic landscape specific for metastatic SDHB-PPGLs. DNA methylation levels were found significantly higher in metastatic SDHB-PPGLs than in SDHB-PPGLs without metastases. One such change included long-range de novo methylation of the PCDHA, PCDHB, and PCDHG gene clusters. High levels of PCDHGC3 promoter methylation were validated in primary metastatic SDHB-PPGLs, it was found amplified in the corresponding metastases, and it was significantly correlated with PCDHGC3 reduced expression. Interestingly, this epigenetic alteration could be detected in primary tumors that developed metastasis several years later. We also show that PCDHGC3 down regulation engages metastasis-initiating capabilities by promoting cell proliferation, migration, and invasion. Conclusions: Our data provide a map of the DNA methylome episignature specific to an SDHB-mutated cancer and establish PCDHGC3 as a putative suppressor gene and a potential biomarker to identify patients with SDHB-mutated cancer at high risk of metastasis who might benefit from future targeted therapies.

Filiaciones:
Bernardo-Castineira C:
 Hosp Univ Cent Asturias, Head & Neck Oncol Lab, Oviedo 33011, Spain

 Inst Oncol Asturias, Oviedo 33006, Spain

 Inst Sanit Res Principado Asturias, Oviedo 33011, Spain

 Ctr Invest Biomed Red Oncol, Oviedo 33011, Spain

Valdes N:
 Hosp Univ Cent Asturias, Serv Endocrinol & Nutr, Oviedo 33011, Spain

Celada L:
 Hosp Univ Cent Asturias, Head & Neck Oncol Lab, Oviedo 33011, Spain

 Inst Sanit Res Principado Asturias, Oviedo 33011, Spain

 Ctr Invest Biomed Red Oncol, Oviedo 33011, Spain

Martinez A:
 Inst Sanit Res Principado Asturias, Oviedo 33011, Spain

Saenz-de-Santa-Maria I:
 Hosp Univ Cent Asturias, Head & Neck Oncol Lab, Oviedo 33011, Spain

 Inst Oncol Asturias, Oviedo 33006, Spain

 Inst Sanit Res Principado Asturias, Oviedo 33011, Spain

Bayon G:
 Inst Sanit Res Principado Asturias, Oviedo 33011, Spain

 Hosp Univ Cent Asturias, Canc Epigenet Lab, Oviedo 33011, Spain

Fernandez A:
 Inst Sanit Res Principado Asturias, Oviedo 33011, Spain

 Hosp Univ Cent Asturias, Canc Epigenet Lab, Oviedo 33011, Spain

Sierra M:
 Inst Oncol Asturias, Oviedo 33006, Spain

 Inst Sanit Res Principado Asturias, Oviedo 33011, Spain

 Hosp Univ Cent Asturias, Canc Epigenet Lab, Oviedo 33011, Spain

Fraga M:
 Inst Sanit Res Principado Asturias, Oviedo 33011, Spain

 Univ Oviedo, Spanish Council Sci Res, Nanomat & Nanotechnol Res Ctr, Oviedo 33007, Spain

Astudillo A:
 Inst Sanit Res Principado Asturias, Oviedo 33011, Spain

 Hosp Univ Cent Asturias, Serv Pathol, Oviedo 33011, Spain

Jimenez-Fonseca P:
 Inst Sanit Res Principado Asturias, Oviedo 33011, Spain

 Hosp Univ Cent Asturias, Serv Med Oncol, Oviedo 33011, Spain

Ria J:
 Hosp Univ Cent Asturias, Serv Neurosurg, Oviedo 33011, Spain

Hevia M:
 Hosp Univ Cent Asturias, Serv Med Oncol, Oviedo 33011, Spain

 Hosp Univ Cent Asturias, Serv Urol Surg, Oviedo 33011, Spain

Turienzo E:
 Hosp Univ Cent Asturias, Serv Surg, Oviedo 33011, Spain

Bernardo C:
 Hosp Univ Cent Asturias, Serv Surg, Oviedo 33011, Spain

Forga L:
 Complejo Univ Navarra, Serv Endocrinol & Nutr, Pamplona 31008, Spain

Tena I:
 Hosp Prov Castellon, Med Oncol Serv, Castellon de La Plana 12002, Spain

Molina-Garrido M:
 Hosp Gen Virgen Luz, Unit Canc Elderly, Cuenca 16002, Spain

Villabona C:
 Hosp Univ Bellvitge, Serv Endocrinol & Nutr, Barcelona 08907, Spain

Serrano T:
 Hosp Univ Bellvitge, Serv Pathol, Barcelona 08907, Spain

Scola B:
 Hosp Gregorio Maranon, Serv Head & Neck Surg, Madrid 28007, Spain

Chirivella I:
 Hosp Clin Univ Valencia, Unit Genet Counsel Canc, Valencia 46010, Spain

del Olmo M:
 Hosp Univ Le Fe, Serv Endocrinol & Nutr, Valencia 46026, Spain

Menendez C:
 Hosp Cabuenes, Serv Pathol, Gijon 33394, Spain

Navarro E:
 Hosp Univ Virgen Rod, Serv Endocrinol, Seville 41013, Spain

Tous M:
 Hosp Virgen Macarena, Unidad Gest Clin Endocrinol & Nutr, Seville 41009, Spain

Vallejo A:
 Hosp Virgen Macarena, Unidad Gest Clin Pathol, Seville 41009, Spain

Athimulam S:
 Mayo Clin, Div Endocrinol Diabet Metab & Nutr, Rochester, MN 55905 USA

Bancos I:
 Mayo Clin, Div Endocrinol Diabet Metab & Nutr, Rochester, MN 55905 USA

Suarez C:
 Inst Oncol Asturias, Oviedo 33006, Spain

 Inst Sanit Res Principado Asturias, Oviedo 33011, Spain

Chiara M:
 Hosp Univ Cent Asturias, Head & Neck Oncol Lab, Oviedo 33011, Spain

 Inst Oncol Asturias, Oviedo 33006, Spain

 Inst Sanit Res Principado Asturias, Oviedo 33011, Spain

 Ctr Invest Biomed Red Oncol, Oviedo 33011, Spain
ISSN: 0021972X





JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Editorial
Oxford University Press, 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 104 Número: 11
Páginas: 5673-5692
WOS Id: 000497979600083
ID de PubMed: 31216007

MÉTRICAS